Hearing impairment in young and middle-aged septicemia survivors

Chun-Gu Cheng, MD^{a,b,c,*}, Wu-Chien Chien, PhD^{d,e,f}, Hung-Che Lin, MD^{g,f}, Hui-Chen Lin, PhD^h, Chi-Hsiang Chung, PhD^{d,e}, Chun-An Cheng, PhD^h

Abstract

The ability of sepsis to induce acute phase hearing impairment has been evaluated in septic and sepsis-surviving mice. The relationship between septicemia and long-term hearing impairment remains unknown in humans.

The data were obtained from the Taiwan Longitudinal National Health Insurance Database from 2000 to 2013. We identified patients suffering from septicemia after discharge, excluding those younger than 18 years old and older than 65 years old. The comparison group was matched based on age, sex, and comorbidities. The outcome was hearing impairment occurring after septicemia. The risk factors associated with hearing impairment were established using multivariate Cox proportional hazard regression.

Our study found that septicemia associated with hearing impairment had an adjusted hazard ratio (HR) of 53.11 (95% confidence interval [CI]: 41.74–67.59). The other factors related to hearing impairment in young and middle-aged septicemia survivors included male sex (adjusted HR 1.31 [95% CI: 1.14–1.5]), chronic kidney disease (adjusted HR 1.63 [95% CI: 1.38–1.94]), and otoscleroisis (adjusted HR 231.54 [95% CI: 31.61–1695.8]).

Our study revealed that septicemia was associated with increased development of hearing impairment in young and middle-aged humans in the long term. Clinicians should be aware of long-term septicemia-related hearing impairment and provide prevention strategies for otopathy in septicemia survivors.

Abbreviations: CI = confidence interval, HR = hazard ratio, ICD-9-CM = International Classification of Disease, Ninth Revision, Clinical Modification, NHIRD = National Health Insurance Research Database.

Keywords: hearing impairment, risk, septicemia

Editor: Gunjan Arora.

The authors report no conflicts of interest.

Supplemental Digital Content is available for this article.

The data that support the findings of this study are available from a third party, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are available from the authors upon reasonable request and with permission of the third party.

^a Department of Emergency Medicine, Taoyuan Armed Forces General Hospital, National Defense Medical Center, Taoyuan, ^b Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, ^c Department of Emergency and Critical Medicine, Wan Fang Hospital, Taipei Medical University, ^d Department of Medical Research, Tri-Service General Hospital, ^e School of Public Health, ^f Graduate Institute of Life and Medical Sciences, ^g Department of Otolaryngology-Head and Neck Surgery, ^h Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

^{*} Correspondence: Chun-An Cheng, Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (e-mail: cca@ndmctsgh.edu.tw).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Cheng CG, Chien WC, Lin HC, Lin HC, Chung CH, Cheng CA. Hearing impairment in young and middle-aged septicemia survivors. Medicine 2020;99:29(e21050).

Received: 24 January 2020 / Received in final form: 26 May 2020 / Accepted: 30 May 2020

http://dx.doi.org/10.1097/MD.00000000021050

1. Introduction

Septicemia is a severe life-threatening disorder that can cause short- and long-term major adverse cardiovascular events, including myocardial infarction, ischemic stroke, and death.^{[1– ^{3]} Septicemia has a high incidence of critical care hospitalization. Septicemia survivors display a range of disabilities and problems that can alter quality of life.^[4] Acute hearing loss is related to sepsis and sepsis survival in mice,^[5,6] but a correlation between septicemia and long-term hearing impairment has not been previously addressed in humans. The aim of this study was to identify whether hearing impairment is related to septicemia in humans.}

Potential causes of hearing loss include aging, genetics, trauma, ototoxic medication, local infections, vascular diseases, autoimmune disorders, and noise. In animal studies, general inflammation leads to apoptosis in Corti organ-supporting cells, which then induces glutamate overstimulation in the inner hair cells in septic mice.^[5,6] Aminoglycoside antibiotics are employed for broad-spectrum gram-negative bacterial infection, but they are associated with nephrotoxicity and ototoxicity.^[7] A previous study found that mammalian hair cell repair was limited, and persistent hearing impairment can occur after hair cell injury.^[8] Understanding the risk factors for hearing impairment is important for preserving function.

We hypothesized that septicemia increases the risk of hearing impairment in young and middle-aged humans. We used the Taiwanese National Health Insurance Research Database (NHIRD) to explore whether a history of septicemia is associated with a subsequent increase in the long-term risk of developing hearing impairment.

2. Methods

National health insurance has been implemented in Taiwan since 1995; it is composed of a unified government supportive health care system and covers approximately 99% of Taiwan's 23 million citizens. All medical care providers must submit computerized data claims for insurance payments. The Taiwanese NHIRD contains all outpatient and inpatient medical insurance payment records. For each visit, the system includes up to 5 International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) inpatient diagnosis and procedure codes and 3 outpatient ICD-9-CM diagnosis and procedure codes. The data extracted included each patient's age, sex, comorbid conditions, hearing impairment codes, and times of admission and discharge.

The dataset used in this study was obtained from the Taiwan Longitudinal Health Insurance Database, which randomly selects patients from the population. We identified patients with diagnosis codes for septicemia (ICD-9-CM as 038, 003.1, 036.1), which were collected from January 1, 2000, to December 31, 2013. The diagnosis code of septicemia in the NHIRD was used for verification.^[2,9–11] Furthermore, hearing loss in children and older patients was reported in 1 pneumococcal meningitis survey.^[12] Age-related hearing loss is caused by the loss of inner ear hair cells over time. In addition, 40% of elderly adults have hearing impairment after age 65.^[13] We excluded patients based

on the following criteria: younger than 18 years, older than 65 years, death during admission, hospitalization for septicemia, hearing impairment before the index date and unknown sex. The date of admission for septicemia was defined as the index date of the study group. Four controls were matched to each case based on age, sex, and comorbidities. Hearing impairment events were defined with the ICD-9-CM diagnostic code 389. Patients were followed until the first event or December 31, 2013. The flow chart of the study is presented in Figure 1.

We used the ICD-9-CM codes to identify diagnoses in the NHIRD for hearing impairment comorbidities. Hearing impairment comorbid disorders mapped by ICD-9-CM codes included hypertension (401–405); diabetes mellitus (250); chronic kidney disease (580–589); hyperlipidemia (272); auto-immune disorders (710); anemia (280, 285); hematological disorders, including coagulopathies and platelet disorders (286–287); coronary artery disease (410–414); ischemic stroke (433–437); meningitis (320–322, 013.0, 036.0, 053.0, 047); traumatic brain injuries (800, 803–805, 850–854); encephalopathy (293, 348.3, 780.01, 780.09); chronic otitis media (381–382); otosclerosis (387); and osteoporosis (733.0). The study was approved by TSGH IRB 2-105-05-025.

2.1. Statistical analyses

Continuous variables are displayed as the means \pm standard deviations and were evaluated with Student *t* tests, while categorical variables are displayed as percentages and were evaluated with the Chi-square (X^2) test. The risk factors for



Table 1 Characteristics of the study population at baseline.

	Septicemia	Septicemia-free	
Variables	n	n	Р
Total	4356	17,424	
Sex			.999
Male	2161 (49.61%)	8644 (49.61%)	
Female	2195 (50.39%)	8780 (50.39%)	
Age (yr)	47.97 <u>+</u> 11.71	47.66±12.72	.144
Age group (yr)			.999
18–44	1339 (30.74%)	5356 (30.74%)	
≥45	3017 (69.26%)	12,068 (69.26%)	
Diabetes mellitus	1148 (26.35%)	4495 (25.8%)	.453
Hypertension	275 (6.31%)	1217 (6.98%)	.117
Chronic kidney disease	528 (12.12%)	2097 (12.04%)	.876
Hyperlipidemia	56 (1.29%)	222 (1.27%)	.94
Coronary heart disease	390 (8.95%)	1557 (8.94%)	.972
Ischemic stroke	82 (1.88%)	272 (1.56%)	.14
Autoimmune diseases	46 (1.06%)	186 (1.07%)	.934
Anemia	171 (3.93%)	611 (3.51%)	.187
Hemtological disorder	65 (1.49%)	241 (1.38%)	.565
Meningitis	29 (0.67%)	110 (0.63%)	.831
Traumatic brain injury	78 (1.79%)	272 (1.56%)	.281
Encephalopathy	5 (0.11%)	9 (0.05%)	.174
Chronic otitic media	681 (15.63%)	2877 (16.51%)	.162
Otoscleroisis	0	4 (0.02%)	.59
Osteoporosis	5 (0.11%)	20 (0.11%)	.999
Location			<.001*
Northern Taiwan	1277 (29.32%)	6951 (39.89%)	
Middle Taiwan	976 (22.41%)	4753 (27.28%)	
Southern Taiwan	1791 (41.12%)	4663 (26.76%)	
Eastern Taiwan	304 (6.98%)	969 (5.56%)	
Outlets islands	8 (0.18%)	88 (0.51%)	
Urbanization level			<.001*
1 (Highest)	1832 (42.06%)	6334 (36.35%)	
2	1908 (43.8%)	7148 (41.02%)	
3	142 (3.26%)	1303 (7.48%)	
4 (Lowest)	474 (10.88%)	2639 (15.15%)	
Level of care			<.001*
Hospital centre	2093 (48.05%)	5437 (31.20%)	
Regional hospital	1483 (34.04%)	4942 (28.36%)	
Local hospital	780 (17.91%)	7045 (40.43%)	
*			

[™] P<.05.

hearing impairment were assessed using Cox proportional hazard regression. The statistical significance was set at P < .05. The statistical analyses were performed with SPSS version 21 software.

3. Results

We investigated 4356 septicemia survivors in the study group and 17,424 septicemia-free patients in the control group. The median hearing impairment detection times were 3.51 years in the study group and 7.72 years in the control group. Table 1 presents the demographic variables for the septicemia and control groups. Compared with the control patients, more septicemia patients were admitted to medical centres, lived in southern Taiwan and had a higher urbanization level. In total, 18.2% (793/4356) of the patients in the study group had hearing impairment versus 0.43% (75/17,424) in the control group (log-rank test: P < .001) (Fig. 2). The majority of hearing impairment cases occurred within 1 year after septicemia (Table 2).



Figure 2. Kaplan–Meier for cumulative incidence of hearing loss between aged 18 and 65 stratified by septicemia with log-rank test.

Table 2

Numbers of hearing loss cases in septicemia and septicemia-free patients.

Septicaemia	With (N = 4356)	Without (N = 17,424)	
In the tracking of x year (s)	Number of hearing impairment cases		
1	257	3	<.001
2	307	7	<.001
3	375	12	<.001
4	426	17	<.001
5	466	25	<.001
6	507	28	<.001
7	547	34	<.001
8	600	40	<.001
9	632	45	<.001
10	675	50	<.001
11	718	57	<.001
12	747	62	<.001
13	770	74	<.001
14	793	75	<.001

Our study revealed a relationship between septicemia and hearing impairment, with an adjusted hazard ratio (HR) of 53.11 (95% confidence interval [CI]: 41.74-67.59). Other risk factors included male sex (adjusted HR 1.31 [95% CI: 1.14-1.5]), chronic kidney disease (adjusted HR 1.63 [95% CI: 1.38-1.94]), and otoscleroisis (adjusted HR 231.54 [95% CI: 31.61-1695.8]), after adjustment for age and other comorbidities. Some underlying diseases were associated with a lower risk of hearing impairment, including hypertension (adjusted HR 0.462 [95% CI: 0.376-0.569]), anemia (adjusted HR 0.646 [95% CI: 0.446-0.937]), and traumatic brain injury (adjusted HR 0.422 [95% CI: 0.233-0.766]) (Table 3). The overall and subgroup-specific incidence rates and incidence rate ratios of hearing impairment between septicemia and septicemia-free patients were performed in Table 4. The overall incidence rates of hearing impairment in septicemia patients were 1477.96 per 10⁵ person-years and 39.11 per 10⁵ person-years in septicemia-free patients. The incidence rate ratio of hearing impairment was 37.79 between septicemia

Variables	Crude HR	95% CI	Р	Adjusted HR	95% CI	Р
Septicemia	55.774	43.995–70.707	<.001*	53.114	41.738-67.591	<.001*
Sex						
Male	1.012	0.886-1.157	.856	1.310	1.144–1.5	<.001*
Female	Reference			Reference		
Age group (yr)						
18–44	Reference			Reference		
≥45	1.146	0.964-1.362	.123	1.193	0.998-1.426	.053
Diabetes mellitus	1.759	1.525-2.030	<.001*	1.154	0.991-1.344	.065
Hypertension	0.474	0.389-0.577	<.001*	0.462	0.376-0.569	<.001*
Chronic kidney disease	3.725	3.146-4.41	<.001*	1.634	1.375-1.942	<.001*
Hyperlipidemia	0.297	0.154-0.573	<.001*	0.561	0.286-1.098	.092
Coronary heart disease	0.804	0.623-1.037	.093	0.843	0.651-1.093	.197
Ischemic stroke	0.595	0.382-0.927	.022	0.715	0.456-1.119	.142
Autoimmune diseases	3.491	2.129-5.725	<.001*	1.241	0.749-2.057	.402
Anemia	0.743	0.513-1.075	.115	0.646	0.446-0.937	.021*
Hematological disorder	2.368	1.396-4.016	.001*	1.555	0.912-2.654	.105
Meningitis	0.843	0.119-5.988	.864	0.657	0.092-4.69	.676
Traumatic brain injury	0.288	0.159-0.523	<.001*	0.422	0.233-0.766	.005*
Encephalopathy	0.595	0.149-2.385	.464	0.543	0.135-2.181	.39
Chronic otitic media	2.087	1.150-3.785	.015	0.840	0.460-1.536	.572
Otoscleroisis	25.583	3.592-182.201	.001	231.538	31.613-1,695.798	<.001*
Osteoporosis	0.000	-	.164	0.000	-	.898
Location						
Northern Taiwan	Reference			Multicollinearity with urbanization level		
Middle Taiwan	0.884	0.736-1.061	.185			
Southern Taiwan	1.436	1.224-1.685	<.001*			
Eastern Taiwan	1.269	0.973-1.657	.079			
Outlets islands	1.285	0.479-3.448	.618			
Urbanization level						
1 (Highest)	1.369	1.121-1.671	.002*	0.706	0.606-0.823	<.001*
2	0.960	0.785-1.172	.686	0.589	0.417-0.833	.003 [*]
3	0.663	0.464-0.948	.024*	0.828	0.663-1.033	.095
4 (Lowest)	Reference			Reference		
Level of care						
Hospital centre	1.466	1.208-1.78	<.001*	1.011	0.862-1.186	.891
Regional hospital	1.269	1.046-1.538	.015	0.995	0.803-1.233	.964
Local hospital	Reference			Reference		

CI = confidence interval, HR = hazard ratio.

P < .05

and septicemia-free patients. Factors of hearing impairment stratified by variables using Cox regression showed in Supplemental Table 1 (see Table, http://links.lww.com/MD/E524, Supplement Content, which illustrates factors of hearing impairment stratified by variables using Cox regression).

4. Discussion

Our study revealed that septicemia is significantly associated with long-term subsequent hearing impairment in young and middleaged adult humans. Hearing impairment occurred earlier in septicemia survivors than in septicemia-free patients. Hearing impairment results from complex processes and may influence communication, which can be very stressful and lead to social withdrawal, affecting patients' quality of life.^[14]

Septicemia can develop when an infection occurs elsewhere in the body. This is dangerous because the bacteria and their toxins can be carried through the bloodstream to the entire body. Septicemia leads to extensive host defense systemic inflammatory responses to fight the infection; when inflammation fails to resolve, it progresses to chronic inflammation, which can persist for months to years.^[15] Inflammation causes blood clots and prevents oxygen from reaching vital organs, resulting in organ failure. Toxins can cause extremely low blood flow, which may result in organ or tissue damage.^[16] Chronic inflammation associated with septicemia can cause short- and long-term atherosclerotic events,^[1-3] dementia,^[9] and multiple sclerosis.^[11]

The oxygen stress attributed to reactive oxygen species generation causes mitochondrial dysfunction via adenosine triphosphate depletion in patients with sepsis.^[17] Hearing impairment in the context of septicemia occurs due to immune reaction-induced apoptosis and microthrombosis following inner ear destruction. Apoptosis occurs in Deiters' cells, Claudius' cells, and Hensen's cells in the Corti organ due to glutamine overstimulation in the radial dendrites; this is followed by vacuolization of the inner ear cells, which has been observed via immunohistochemical evaluation through a cecal ligation puncture in an induced sepsis mouse study.^[5] Sepsis-surviving model mice exhibited an increased threshold of auditory brainstem response.^[6] Aminoglycoside antibiotics are widely used for suspected gram-negative bacterial infections. A previous study found that vasodilation due to inflammation increased

Table 4

The overall and subgroup-specific incidence rates and incidence rate ratios of hearing impairment between septicemia and septicemia	a-
free patients.	

Tabl 793 53865.21 1477.96 75 191750.96 33.11 37.79 Mile 380 2131.57 1782.7 39 94128.71 141.45 450.3 Alge graup for	Septicemia Stratified	With Event	PYs	Incidence Rate (per 10 ⁵ PYs)	Without Event	PYs	Incidence Rate (per 10 ⁵ PYs)	IRR
Gambar Second Seco	Total	793	53655.21	1477.96	75	191750.96	39.11	37.79
Make 380 21315.97 1722.7 99 9418.87.1 14.13 432.03 Age group b/1 1727.09 98 99702.26 36.88 34.83 Age group b/1 1727.09 98 99702.26 36.88 34.83 B-4.4 152 10002.15 1516.34 6 39657.36 15.16 100 2:16 0.11 3387.06 1448.15 15 35784.25 41.95 32.36 Without 52 35504.86 1448.93 60 15504.01 39.36 43.92 Without 71 3384.66 724.17 1 49277.66 34.93 18.32 Without 707 708.574 1010.9 72 144807.54 38.95 38.75 Without 707 2088.44 1010.9 72 144807.54 39.49 38.22 30.88 Without 707 2088.45 1010.27 100.27 32.73 30.49 Without 74 <	Gender							
Female 413 2239.24 1277.09 36 9782.26 36.88 94.63 18-44 152 1002.415 151.63.4 6 39667.36 151.6 100 28-65 641 4631.06 1498.15 15 35764.25 41.95 326.4 Without 52 139.46 1498.5 15 35764.25 41.95 326.4 Without 696 4.0200.05 77.97.7 67 144820.11 39.36 43.52 Without 696 4.0200.05 724.17 18 4690.95 38.6 88.75 Without 167 4.0638.45 1342.3 74 182770.63 40.49 33.15 Without 177 5208.94 138.15 3 6894.35 43.59 88.7 Without 178 5208.94 138.15 3 6894.35 43.59 88.7 Without 179 5208.96 1571.14 68 17071.4 39.49 38.77	Male	380	21315.97	1782.7	39	94128.71	41.43	43.03
Ape group (b) Ape group (b) Ape group (b) Ape group (b) App grou	Female	413	32339.24	1277.09	36	97622.26	36.88	34.63
16-4 152 1002,15 1516,34 6 39667,36 15.16 100 245 641 6931,06 1409,14 99 15/181,61 45,34 32,4 Deantes mellulas 1814,8,5 1498,15 15 357,4,25 41,95 34,46 Wehn 261 1814,8,55 1498,15 15 357,4,25 41,95 34,28 Wehn 96 40260,55 728,17 18 4493,05 33,35 18,88 Chenic Kulbry disease Wehn 167 7018,76 237,93,4 1 847,34 11,14 21,35 Wehn 167 7018,76 739,34 1 847,34 84,55 83,57 Wehn 6 1556,37 385,51 3 687,44 84,65 88,79 88,57 Wehn 6 1563,7 385,51 3 687,44 88,85 88,79 Wehn 16 2043,37 109,28 69 144,81,74 88,85	Age group (yr)							
2+6 6+1 43831.06 1.489.14 60 152183.61 45.34 23.4 Mithout 52 3550.66 1498.3 60 155996.71 38.46 38.86 Mithout 97 13394.66 1728.74 57 144820.11 39.36 43.85 Mithout 96 40590.65 1728.74 57 144820.11 39.36 43.85 Mithout 96 40590.65 1728.74 57 144820.61 39.45 33.15 Mithout 166 40596.65 1342.3 74 182770.63 40.49 33.15 Mithout 78 5098.74 150.99 72 184807.54 38.95 88.75 Mithout 78 1509.26 197.174 69 17471.6 39.49 88.52 98.82 Without 778 5288.96 1471.54 74 199.49 38.42 39.49 88.52 30.88 39.49 38.42 39.49 38.42 39.49 <td< td=""><td>18–44</td><td>152</td><td>10024.15</td><td>1516.34</td><td>6</td><td>39567.36</td><td>15.16</td><td>100</td></td<>	18–44	152	10024.15	1516.34	6	39567.36	15.16	100
Dealines melluls Use of the set of th	≥45	641	43631.06	1469.14	69	152183.61	45.34	32.4
Winout 552 36200.866 1498.3 60 155966.71 38.46 38.98 Winout 606 60200.55 1728.74 57 144820.11 39.36 43.82 Winout 606 40200.55 1728.74 7 144820.11 39.36 38.35 18.88 Contoc kidray disease Winout 626 46036.64 1342.3 74 182776.63 40.04.9 33.16 Winout 78 52008.84 150.05.9 72 1944875.4 38.85 88.57 Concary direg videase Winout 735 46322.06 1521.04 69 194365.07 37.43 40.22 Winout 735 46322.06 1521.04 69 19436.07 37.43 40.22 Winout 779 51613.87 1500.92 69 19436.07 37.43 40.22 Winout 779 51613.87 1509.62 69 19437.125 37.61 40.12 Winout 748 52669.9	Diabetes mellitus							
Win 251 18.46.3.5 143.1.5 1.5 3.3754.2.5 4.1.9.5 44.2.8 Windurt 696 40260.5.5 17.28.7.4 5.7 14.4620.1.1 39.3.6 43.2.8 Winn 9.7 1339.4.66 724.17 1.8 46630.85 38.3.5 18.2.8 Winn 1.67 7018.7.6 2379.3.4 1 8974.3.4 11.1.4 213.5.5 Winn 1.67 7018.7.6 2379.3.4 1 8974.3.4 11.1.4 213.5.5 Winnut 7.97 52008.84 1510.6.9 7.2 18487.5.4 38.0.5 38.7.9 Winnut 7.97 5208.84 1500.5.8 6.9 18432.6.07 37.4.3 40.3.2 8.8.5 Corresery arthy disease	Without	532	35506.86	1498.3	60	155996.71	38.46	38.96
Hyperhesion Hyperhesion Without 60 128.74.7 18 40820.85 38.35 18.88 Cornols clarge yieldsesse Hithout 626 46630.45 1342.3 74 182.776.63 40.49 33.16 Without 626 46630.45 1342.3 74 182.776.63 40.49 33.16 Without 787 520.06.8.4 1510.59 72 16.4667.54 38.85 8.85 Corroary attry videase Without 73 423.22.06 1521.04 69 174.716 39.49 38.52 Without 735 423.22.06 1521.04 69 1243.26.07 37.43 40.32 Without 778 5563.03 1007.54 69 1243.26.07 37.43 40.32 Without 778 5563.05 1970.22 1 698.19 143.23 13.43 Aberian 72 12643.05 77.43 40.32 14.93 Without 778 5268.09	With	261	18148.35	1438.15	15	35754.25	41.95	34.28
Milhnut 696 44020.05 17.28.74 57 14.4820.11 39.36 43.25 Without 626 46939.65 73.47 18 4800.85 38.35 18.88 Chronic Kidney disease 4 11.14 213.55 40.49 33.15 Without 67 7018.76 239.34 1 8974.34 11.14 213.55 Without 67 13566.37 385.51 3 6883.42 33.85 88.75 Without 68 5333.15 1087.54 69 1747.16 39.49 35.22 Without 779 51618.87 1599.29 69 184.026.07 37.43 40.32 Without 778 52869.96 1471.51 74 190.62.77 38.73 37.99 Without 778 52869.96 1471.51 74 190.52.7 38.73 38.93 37.84 Accimation 72 190.63.13 1467.94 190.574.53 38.83 37.83	Hypertension							
Winh 97 1339.466 724.17 18 46830.85 38.35 18.88 Winbut 626 46668.45 13.42.3 74 182776.63 40.49 33.15 Winbut 707 5008.84 1510.59 72 18467.54 38.95 38.79 Winbut 6 1556.37 385.51 3 6883.42 43.58 8.85 Coronary artery disease	Without	696	40260.55	1728.74	57	144820.11	39.36	43.92
Chronic kindney disease Without 626 4608.45 1342.3 74 182776.63 40.49 13.15 With 167 7018.76 2379.34 1 82776.63 40.49 131.15 Without 787 5208.84 1510.59 72 184.867.54 38.95 88.79 With 6 1508.37 385.51 3 6883.42 43.58 8.85 Corrary artery disease Without 773 4832.206 1521.04 69 174716 39.49 38.22 30.88 Kith 5 613.37 1509.28 69 1742716 39.49 88.22 30.88 Kith 5 6163.37 1509.28 69 184326.07 37.43 40.22 With 14 2041.34 685.83 6 7424.89 80.81 8.9 Without 779 51613.37 1509.28 69 184326.07 37.43 74.9 80.81 8.9 Without 778 52869.96 1471.54 74 191052.77 38.73 75.9 Without 778 52869.96 1471.54 74 191052.77 38.73 75.9 Without 770 51005.35 1509.85 69 183.471.25 37.61 40.14 Without 770 5105.35 1509.85 69 183.471.25 37.61 40.14 Without 770 5105.35 1509.85 109 1 1176.44 85 8.9 3 7.8 Without 770 5105.35 1509.85 109 1 1176.44 85 8.9 3.8 Without 780 5313.91.3 1467.84 74 190674.53 38.83 37.9 Without 780 5313.91.3 1467.84 75 191510.73 39.16 37.77 Without 780 5313.91.3 1467.84 77 190674.53 38.48 37.9 Without 780 5313.91.3 1467.84 77 190674.53 38.48 37.9 Without 781 5348.24 1479.01 75 191510.73 39.16 37.77 Without 781 5348.24 1479.01 75 191510.73 39.16 37.77 Without 781 5348.24 1490.37 75 191500.73 0 - Without 781 5348.24 1490.37 75 191020.36 0 - Without 781 53655.21 1477.96 77 180.04 9.9 39.33 34.41 13.9 Without 783 53655.21 1477.96 75 1900.96.6 39.3.43 74.1 3.90 Without 783 53655.21 1477.96 75 1900.96.6 39.3.43 74.1 3.90 Without 783 53655.21 1477.96 75 1900.96.6 39.3.43 74.1 25.9 Without 783 53655.21 1477.96 75 1900.96.6 39.3.43 74.1 25.9 Without 783 53655.21 1477.96 75 1906.96.6 39.3.43 74.1 25.9 Without 783 53655.21 1477.96 75 1906.96.6 39.3.43 74.1 25.9 Without 783 53655.21 1477.96 75 1906.96.6 39.3.44 74.1 25.9 Without 783 53655.21 1477.96 75	With	97	13394.66	724.17	18	46930.85	38.35	18.88
Mithout 626 4668.645 1342.3 74 127276.83 40.49 33.15 Hyperficientia 7018.76 2373.34 1 8974.34 11.14 213.53 Without 75 52098.84 1510.59 72 14467.54 43.98 88.95 Oronary atray disase 735 40322.05 1521.04 69 17474.6 39.49 35.22 30.88 Without 737 40322.05 1521.04 69 17474.69 35.22 30.88 Stehmic stroke	Chronic kidney disease							
With the set of the s	Without	626	46636.45	1342.3	74	182776.63	40.49	33.15
Hyperfigitation Number 75 Score	With	167	7018.76	2379.34	1	8974.34	11.14	213.53
Without 787 52098.84 1510.59 72 184867.54 38.895 38.79 Without 735 4832.06 1521.04 69 1747116 39.49 35.22 30.88 Without 735 4832.06 1521.04 69 1747116 39.49 35.22 30.88 Ischemic stroke 69 1747116 39.49 30.82 Without 779 51613.87 1509.28 69 174717 38.73 40.32 Without 778 52869.96 1471.15.4 74 191052.77 38.73 37.99 Without 770 51053.5 1509.65 69 183471.25 37.61 40.14 Without 770 5105.9 1509.65 69 183471.25 37.61 40.14 Without 780 53139.13 1467.84 74 190574.53 38.83 37.83 Without 782 5354.04.2 1479.01 75 191510.73	Hyperlipidemia							
With 6 156.37 385.51 3 688.42 43.58 8.55 Coronay atery diseases	Without	787	52098.84	1510.59	72	184867.54	38.95	38.79
Coronary artery diseases Coronary artery diseases Coronary artery disease Sas.ez Sa	With	6	1556.37	385.51	3	6883.42	43.58	8.85
Without 735 48222.06 1521.04 69 17/4716 39.49 38.52 With 58 533.15 1067.54 6 17034.96 35.22 30.86 Without 779 51613.87 1509.28 69 184326.07 37.43 40.32 Without 778 52869.96 1471.54 74 191052.77 38.73 37.99 Without 770 5105.35 1509.65 69 183471.25 37.61 40.14 Mithout 770 51005.35 1509.65 69 183471.25 37.61 40.14 Without 780 53139.13 1467.84 74 190574.53 38.83 77.86 Without 780 53139.13 1467.84 74 190574.53 38.83 77.87 Without 780 53139.13 1467.84 74 190574.53 38.83 77.87 Without 792 53549.42 1479.01 75 191510.73 39.16 <td>Coronary artery disease</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Coronary artery disease							
With 58 533.15 1087.54 6 1703.496 35.22 30.88 Without 779 51613.87 1509.28 69 184326.07 37.43 40.32 Without 778 52689.96 1471.54 74 191052.77 38.73 37.99 Without 778 52689.96 1471.54 74 191052.77 38.73 37.99 Without 70 51005.35 1509.65 69 183471.25 37.61 40.14 Anemia 700 51039.31 1467.84 74 190574.53 38.83 37.89 Without 709 53139.13 1467.84 74 190574.53 38.83 37.8 Without 73 516.08 2519 1 1176.44 85 29.63 Without 792 53649.42 1479.01 75 191510.73 39.16 37.77 Without 785 51606.35 1510.77 72 183048.98 39.33 <t< td=""><td>Without</td><td>735</td><td>48322.06</td><td>1521.04</td><td>69</td><td>174716</td><td>39.49</td><td>38.52</td></t<>	Without	735	48322.06	1521.04	69	174716	39.49	38.52
Ischemic stroke Start 1500 28 69 14426.07 37.43 40.32 With 1 14 2041.34 685.83 6 7424.89 80.81 84.99 Autoimmune diseases	With	58	5333.15	1087.54	6	17034.96	35.22	30.88
Without 779 51613.87 1500.28 69 144326.07 37.43 40.22 With 14 2041.34 685.83 6 7424.89 80.81 84.9 Autoimmune diseases	Ischemic stroke							
With 14 2041.34 685.83 6 7424.89 80.81 8.49 Autoimmune diseases Without 778 52869.96 1471.54 74 191052.77 38.73 37.99 With 75 52869.96 1471.54 74 191052.77 38.73 37.99 With 70 51005.35 1509.65 69 829.72 72.47 11.98 Hemotological disorder With 23 2649.86 867.97 6 8279.72 72.47 11.98 Hemotological disorder With 13 516.08 219 1 1176.44 85 29.63 Mithout 792 53549.42 1479.01 75 19151.073 39.16 37.77 Without 785 5190.35 1510.77 72 183048.98 93.33 34.47 13.69 Encephalogathy Without 781 53432.48 1480.37 75 191020.36 39.26 37.77 Without	Without	779	51613.87	1509.28	69	184326.07	37.43	40.32
Autoimure diseases Seases Seases <thseases< th=""></thseases<>	With	14	2041.34	685.83	6	7424.89	80.81	8.49
Without 778 52860.96 1471.54 774 191052.77 38.73 37.99 With 15 785.25 1910.22 1 698.19 143.23 13.34 Amenia 770 51005.35 1509.65 69 88279.72 37.61 40.14 With 23 2649.86 887.97 6 8279.72 72.47 11.88 Hemotological disorder 780 5313.9.13 1467.84 74 190574.53 38.83 37.8 Without 780 5313.9.13 1467.84 74 190574.53 38.83 37.8 Without 780 5313.9.13 1467.84 74 190574.53 38.83 37.8 Without 792 53549.42 1479.01 75 19151.073 39.16 37.7 With 8 1694.86 472.02 3 8701.98 39.43 37.61 Without 791 53432.48 1480.37 75 191020.36 39.26 37.7 <td>Autoimmune diseases</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Autoimmune diseases							
With 15 785.25 1910.22 1 698.19 143.23 13.34 Anemia	Without	778	52869.96	1471.54	74	191052.77	38.73	37.99
Anemia	With	15	785.25	1910.22	1	698.19	143.23	13.34
Without 770 51005.35 1509.65 69 183471.25 37.61 40.14 With 23 2649.86 867.97 6 8279.72 72.47 11.98 Hemotological disorder	Anemia							
With 23 2649.86 867.97 6 8279.72 72.47 11.88 Hemotological disorder Without 780 53139.13 1467.84 74 190574.53 38.83 37.8 With 13 516.08 2519 1 1176.44 85 29.63 Meningitis Without 792 53549.42 1479.01 75 191510.73 39.16 37.77 With 1 105.79 945.3 0 240.23 0 - Traumatic brain injury Without 785 51960.35 1510.77 72 183048.98 39.33 38.41 With 8 1694.86 472.02 3 8701.98 34.47 13.69 Encephalopathy With 2 222.73 897.95 0 730.6 0 - Without 789 53139.71 1484.77 68 190845.57 35.63 41.67 With 4 515.5 775.94	Without	770	51005.35	1509.65	69	183471.25	37.61	40.14
Hemotological disorder Without 780 53139.13 1467.84 74 190574.53 38.83 37.8 Without 13 516.08 2519 1 1176.44 85 29.63 Meringitis 39.16 37.7 Without 792 53549.42 1479.01 75 191510.73 39.16 37.7 Without 792 53549.42 1479.01 75 191510.73 39.16 37.7 Without 792 53549.42 1470.01 72 183048.98 39.33 38.41 Without 785 51960.35 1510.77 72 183048.98 39.36 34.47 13.69 Encephalopathy 75 191020.36 0 - Without 791 53432.48 1480.37 75 191020.36 0 - Without 793 53139.71 1484.77 68 190845.57 55.63 41.67	With	23	2649.86	867.97	6	8279.72	72.47	11.98
Without 780 53139.13 1467.84 74 190574.53 38.83 37.8 With 13 516.08 2519 1 1176.44 85 29.63 Meningtis	Hemotological disorder							
With 13 516.08 2519 1 1176.44 85 29.63 Meningits	Without	780	53139.13	1467.84	74	190574.53	38.83	37.8
Meringitis Stafen A2 1479.01 75 191510.73 39.16 37.77 With 0 1 105.79 945.3 0 240.23 0 - Traumatic brain injury 785 51960.35 1510.77 72 183048.98 39.33 38.41 With 0 8 1694.86 472.02 3 8701.98 34.47 13.69 Encephalopathy 71 53432.48 1480.37 75 191020.36 39.26 37.7 With 2 2 222.73 897.95 0 730.6 0 - Chronic otitic media 74 191020.36 39.26 37.7 14.67 Without 789 53139.71 1484.77 68 190845.57 35.63 41.67 Otscleroisis 70 0 0 0 1 7.19 13910.97 - Without 793 53584.36 1479.91 75 190660.6 39.34 37.62 Without <td>With</td> <td>13</td> <td>516.08</td> <td>2519</td> <td>1</td> <td>1176.44</td> <td>85</td> <td>29.63</td>	With	13	516.08	2519	1	1176.44	85	29.63
Without 792 53549.42 1479.01 75 191510.73 39.16 37.77 With 1 1 0.579 945.3 0 240.23 0 - Taumatic brain injury	Meningitis							
With 1 105.79 945.3 0 240.23 0 - Traumatic brain injury Traumatic brain injury 785 51960.35 1510.77 72 183048.98 99.33 38.41 With tout 785 51960.35 1510.77 72 183048.98 39.33 38.41 With 8 1694.86 472.02 3 8701.98 34.47 13.69 Encephalopathy Without 791 53432.48 1480.37 75 191020.36 39.26 37.7 With 2 2.22.73 897.95 0 730.6 0 - Chronic otitic media	Without	792	53549.42	1479.01	75	191510.73	39.16	37.77
Traumatic brain injury Without 785 51960.35 1510.77 72 183048.98 39.33 38.41 Without 8 1694.86 472.02 3 8701.98 34.47 13.69 Encephalopathy	With	1	105.79	945.3	0	240.23	0	-
Without 785 51960.35 1510.77 72 183048.98 39.33 38.41 With 8 1694.86 472.02 3 8701.98 34.47 13.69 Encephalopathy	Traumatic brain injury							
With 8 1694.86 472.02 3 8701.98 34.47 13.69 Encephalopathy Without 791 53432.48 1480.37 75 191020.36 39.26 37.7 Without 7 2 222.73 897.95 0 730.6 0 - Chronic otitic media 4 515.5 775.94 7 905.39 773.15 1 Vithout 793 53655.21 1477.96 74 191743.77 38.59 38.3 Without 793 53584.36 1479.91 75 190660.6 39.34 37.62 Without 793 53584.36 1479.91 75 190660.6 39.34 37.62 Without 793 53584.36 1479.91 75 190660.6 39.34 37.62 Urbanization level I Inspiration level I 1 2 59895.13 36.73 49.27 2 303 23911.23	Without	785	51960.35	1510.77	72	183048.98	39.33	38.41
Encephalopathy Without 791 53432.48 1480.37 75 191020.36 39.26 37.7 With 2 222.73 897.95 0 730.6 0 - Chronic ottic media	With	8	1694.86	472.02	3	8701.98	34.47	13.69
Without 791 53432.48 1480.37 75 191020.36 39.26 37.7 With 2 222.73 897.95 0 730.6 0 - Chronic ottiic media	Encephalopathy							
With 2 222.73 897.95 0 730.6 0 - Chronic otitic media - Chronic otitic media -	Without	791	53432.48	1480.37	75	191020.36	39.26	37.7
Chronic otific media 789 53139.71 1484.77 68 190845.57 35.63 41.67 With 4 515.5 775.94 7 905.39 773.15 1 Otoscleroisis Without 793 53655.21 1477.96 74 191743.77 38.59 38.3 With 0 0 0 1 7.19 13910.97 – Osteoporosis - - - - - - - With 0 70.85 0 0 1090.36 0 – Urbanization level - - - - - - - 1 (The highest) 331 18290.62 1809.67 22 59895.13 36.73 49.27 2 303 23911.23 1267.19 40 84908.88 47.11 26.9 3 34 3470.57 979.67 5 14458.62 34.58 28.33 4 (The lowest) </td <td>With</td> <td>2</td> <td>222.73</td> <td>897.95</td> <td>0</td> <td>730.6</td> <td>0</td> <td>-</td>	With	2	222.73	897.95	0	730.6	0	-
Without 789 53139.71 1484.77 68 190845.57 35.63 41.67 With 4 515.5 775.94 7 905.39 773.15 1 Otoscleroisis	Chronic otitic media							
With 4 515.5 775.94 7 905.39 773.15 1 Otoscleroisis 7 905.39 773.15 1 Without 793 53655.21 1477.96 74 191743.77 38.59 38.3 With 0 0 0 1 7.19 13910.97 - Osteoporosis - - - - - - - Without 793 53584.36 1479.91 75 190660.6 39.34 37.62 With 0 70.85 0 0 1090.36 0 - Urbanization level - - - - - - - 1<(The highest)	Without	789	53139.71	1484.77	68	190845.57	35.63	41.67
Otoscleroisis Vithout 793 53655.21 1477.96 74 191743.77 38.59 38.3 With 0 0 0 0 1 7.19 13910.97 - Osteoporosis 0 0 0 1 7.5 190660.6 39.34 37.62 With 0 70.85 0 0 1090.36 0 - Urbanization level 331 18290.62 1809.67 22 59895.13 36.73 49.27 2 303 23911.23 1267.19 40 84908.88 47.11 26.9 3 34 3470.57 979.67 5 14458.62 34.58 28.33 4 (The lowest) 125 7982.79 1565.87 8 32488.34 24.62 63.59 Level of care	With	4	515.5	775.94	7	905.39	773.15	1
Without 793 53655.21 1477.96 74 191743.77 38.59 38.3 With 0 0 0 0 1 7.19 13910.97 - Osteoporosis -	Otoscleroisis	700					22.52	
With 0 0 0 1 7.19 13910.97 - Osteoporosis - <td>Without</td> <td>793</td> <td>53655.21</td> <td>1477.96</td> <td>74</td> <td>191/43.//</td> <td>38.59</td> <td>38.3</td>	Without	793	53655.21	1477.96	74	191/43.//	38.59	38.3
Osteoporosis 793 53584.36 1479.91 75 190660.6 39.34 37.62 With 0 70.85 0 0 1090.36 0 - Urbanization level - - - - - - 1 (The highest) 331 18290.62 1809.67 22 59895.13 36.73 49.27 2 303 23911.23 1267.19 40 84908.88 47.11 26.9 3 34 3470.57 979.67 5 14458.62 34.58 28.33 4 (The lowest) 125 7982.79 1565.87 8 32488.34 24.62 63.59 Level of care	With	0	0	0	1	7.19	13910.97	-
Without 793 53384.36 1479.91 75 190660.6 39.34 37.62 With 0 70.85 0 0 1090.36 0 - Urbanization level	Usteoporosis	700	50504.00		75	100000.0	00.04	07.00
With 0 70.85 0 0 1090.36 0 - Urbanization level 1 (The highest) 331 18290.62 1809.67 22 59895.13 36.73 49.27 2 303 23911.23 1267.19 40 84908.88 47.11 26.9 3 34 3470.57 979.67 5 14458.62 34.58 28.33 4 (The lowest) 125 7982.79 1565.87 8 32488.34 24.62 63.59 Level of care	Without	793	53584.36	1479.91	/5	190660.6	39.34	37.62
Urbanization level 1 (The highest) 331 18290.62 1809.67 22 59895.13 36.73 49.27 2 303 23911.23 1267.19 40 84908.88 47.11 26.9 3 34 3470.57 979.67 5 14458.62 34.58 28.33 4 (The lowest) 125 7982.79 1565.87 8 32488.34 24.62 63.59 Level of care	With	0	70.85	U	0	1090.36	U	-
1 (Ine highest) 331 18290.62 1809.67 22 59895.13 36.73 49.27 2 303 23911.23 1267.19 40 84908.88 47.11 26.9 3 34 3470.57 979.67 5 14458.62 34.58 28.33 4 (The lowest) 125 7982.79 1565.87 8 32488.34 24.62 63.59 Level of care	Urbanization level	001	10000.00	1000.07	22	50005 10	00.70	10.07
2 303 23911.23 1267.19 40 84908.88 47.11 26.9 3 34 3470.57 979.67 5 14458.62 34.58 28.33 4 (The lowest) 125 7982.79 1565.87 8 32488.34 24.62 63.59 Level of care	1 (The highest)	331	18290.62	1809.67	22	59895.13	36.73	49.27
3 34 34/0.57 9/9.67 5 14458.62 34.58 28.33 4 (The lowest) 125 7982.79 1565.87 8 32488.34 24.62 63.59 Level of care	2	303	23911.23	1267.19	40	84908.88	47.11	26.9
4 (Ine lowest) 125 7982.79 1565.87 8 32488.34 24.62 63.59 Level of care Hospital center 322 20519.69 1569.22 30 66266.59 45.27 34.66 Regional hospital 336 23979.04 1401.22 36 83877.64 42.92 32.65 Local hospital 135 9156.48 1474.37 9 41606.73 21.63 68.16	3 4 (The las - 1)	34	34/0.57	9/9.67	5	14458.62	34.58	28.33
Level of care 322 20519.69 1569.22 30 66266.59 45.27 34.66 Regional hospital 336 23979.04 1401.22 36 83877.64 42.92 32.65 Local hospital 135 9156.48 1474.37 9 41606.73 21.63 68.16	4 (The lowest)	125	7982.79	1565.87	8	32488.34	24.62	63.59
Hospital center 322 20519.69 1569.22 30 66266.59 45.27 34.66 Regional hospital 336 23979.04 1401.22 36 83877.64 42.92 32.65 Local hospital 135 9156.48 1474.37 9 41606.73 21.63 68.16	Level of care	000	00540.00	1500.00	66	00000 50	45.07	04.00
Regional nospital 336 239/9.04 1401.22 36 838/7.64 42.92 32.65 Local hospital 135 9156.48 1474.37 9 41606.73 21.63 68.16	Hospital center	322	20519.69	1569.22	30	66266.59	45.27	34.66
Local nospital 135 9156.48 14/4.37 9 41606.73 21.63 68.16	Regional hospital	336	239/9.04	1401.22	36	83877.64	42.92	32.65
	Local hospital	135	9156.48	14/4.3/	9	41606.73	21.63	68.16

IRR = incidence rate ratio, PYs = person-years.

cellular damage in the blood-labyrinth barrier, which facilitates aminoglycoside transfer to hair cells.^[18]

Male humans who perform work that involves exposure to loud noises exhibit an increased risk of hearing loss associated with pneumococcal meningitis.^[12] Our study had a similar finding: men exhibited an increased risk of hearing impairment after septicemia. Sepsis induces apoptosis in various organs, potentially leading to multiple organ failure. The moderate renal impairment-related increased risk of hearing impairment occurs via apoptosis, with an odds ratio of 1.43 (95% CI: 1.1–1.84),^[19] and our study reported a similar finding. A past study reported that otosclerosis related to sensorineural hearing loss occurred in 34% of patients,^[20] and our study showed that otosclerosis also increases hearing impairment. The otosclerosis was the highest association with hearing impairment, but it would not be the major cause instead of septicemia with low prevalence in our study group. Septicemia patients with more comorbid conditions will experience increased mortality during hospitalization,^[10] and an increased number of comorbid conditions seems to cause an increased risk of septicemia-induced hearing impairment in our study.

Patients with a higher urbanization level have a lower risk of hearing impairment. Potential reasons include the possibility that these patients are more concerned about their health status and frequently seek health care providers to improve their quality of life. Patients with hypertension, anemia, and traumatic brain injury exhibited relatively fewer hearing impairment events in the present study. The potential reason may be adequate treatment indicated by the diagnostic codes for hypertension and anemia in the claims data. Higher mortality from traumatic head injury leads to a lower risk of hearing impairment. More in-depth research in this field is necessary.

Aging and exposure to loud noise may cause wear and tear on the hairs or nerve cells in the cochlea, which send sound signals to the brain. In addition, the aging immune system and weaker older bodies are more vulnerable to the damaging effects of sepsis, and these patients are more likely to suffer lasting consequences. We excluded older septicemia survivors to reduce the effect of aging on hearing impairment. However, our study found that hearing impairment was not associated with older age in the young and middle-aged groups. Poorly controlled diabetes mellitus induces chronic kidney disease and increases oxidative stress.^[21] Diabetes mellitus and hyperlipidemia were not related to heading impairment in adults in our study. A potential reason is that the NHIRD dataset is generated from insurance payment claims. Patients with a diagnosis of diabetes mellitus and hyperlipidemia are administered suitable treatments according to the payment guidelines. Spiral ganglion loss and a flattened organ of Corti were noted after ischemia in guinea pigs.^[22] A previous rat study showed cell damage due to apoptosis in outer hair cells in a carotid ischemia model.^[23] However, our study did not find that ischemic stroke increased the risk of hearing impairment. The potential reason is that hearing impairment may be undiagnosed or underestimated in severe ischemic stroke patients who are bedridden or display cognitive impairment without hearing impairment complaints.

Bacterial infection can be prevented with a vaccine^[24,25] and treated with antibiotics. Rapid identification of the infection source can facilitate timely treatment with appropriate antibiotics, potentially preserving some hearing function. The administration of third-generation cephasporin antibiotics to treat acute infection has relatively fewer toxic effects on the ear.

Dextrans and vasodilators improve inner ear circulation. Aspirin reduces ischemic attacks within 1 month after sepsis.^[26] Antioxidants diminish reactive oxygen species levels to reduce hair cell apoptosis.^[27]

Our results support the hypothesis of a close correlation between septicemia and hearing impairment in the largest population of participants investigated to date, after adjustment for other contributing factors. Physicians and patients need to pay more attention to this complication of septicemia. The rapid identification of the infection source can quickly facilitate treatment with appropriate antibiotics, and guidelines on the management of chronic kidney disease^[28] should be followed to preserve hearing function, thereby enhancing patients' ability to communicate and relieving their psychological burden. If treatment for hearing loss fails, adults may need a cochlear implant to improve their hearing ability and, thereby, their social interactions. However, this alternative can be uncomfortable and expensive.

5. Limitations

There were some limitations of this study. First, because the NHIRD is a payment claims dataset, detailed data on body mass index, noise environment exposure, family history, potential risk factors, and severity of the hearing loss according to audiometry and otological exams were not available; however, these factors may have an impact on hearing impairment risk.

Second, the diagnoses of septicemia, hearing impairment, and comorbidities were made according to the ICD-9-CM diagnostic codes recorded in the database from the Taiwan NHI program, which may vary from study to study. Patients with severe septicemia experience severe inflammation, which may exert a threshold effect on hearing impairment. A prospective audiometry assessment must be undertaken in septicemia survivors to confirm the dose effect.

Third, age-related hearing impairment occurs after 55 years of age. The etiology of hearing impairment needs to be determined in older septicemia survivors.

Fourth, we did not survey ototoxic agents in this study. The effects of ototoxic agents, such as antibiotics or diuretics, on hearing impairment should be assessed in the future.

Fifth, although the data were only collected until 2013, they still provide initial results regarding the risk of hearing impairment among septicemia survivors. One study showed lesser poor hearing in older severe sepsis survivors compared with general population in USA.^[29] This pilot study was performed in a Chinese population, and the generalizability of our findings to other ethnic populations is limited. It needs more recent data and further global study to confirm our findings.

6. Conclusions

To the best of our knowledge, this is the first paper to show that septicemia is associated with an increased risk of long-term hearing loss in young and middle-aged humans. Our study suggests that clinicians should be aware of septicemia-related hearing impairment and use optimal prophylaxis strategies to decrease hearing impairment. We recommend determining the hearing of septicemia survivors to enable the earlier identification of hearing impairment. Early aggressive prevention and treatment of septicemia should be used to reduce long-term complications and improve quality of life.

Acknowledgments

The authors thank TSGH-C107-004, TSGH-C108-003, and TSGH-C109-010 for their support and the American Journal Experts for English editing.

Author contributions

Conceptualization: Chun-Gu Cheng, Hung-Che Lin, Chun-An Cheng.

Data curation: Chun-Gu Cheng, Wu-Chien Chien.

Formal analysis: Chi-Hsiang Chung.

Funding acquisition: Wu-Chien Chien.

Investigation: Wu-Chien Chien, Hung-Che Lin, Chun-An Cheng. Methodology: Wu-Chien Chien.

Project administration: Hui-Chen Lin.

Resources: Wu-Chien Chien.

Software: Wu-Chien Chien.

Supervision: Chun-An Cheng.

Validation: Wu-Chien Chien, Hung-Che Lin, Chi-Hsiang Chung.

Visualization: Chi-Hsiang Chung.

Writing – original draft: Chun-Gu Cheng.

Writing - review & editing: Hui-Chen Lin, Chun-An Cheng.

References

- Walkey AJ, Wiener RS, Ghobrial JM, et al. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 2011;306:2248–54.
- [2] Cheng CA, Cheng CG, Lin HC, et al. New-onset atrial fibrillation related ischemic stroke occurring after hospital discharge in septicemia survivors. QJM 2017;110:453–7.
- [3] Walkey AJ, Hammill BG, Curtis LH, et al. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest 2014;146:1187–95.
- [4] Donnelly JP, Safford MM, Shapiro NI, et al. Application of the third international consensus definitions for sepsis (sepsis-3) classification: a retrospective population-based cohort study. Lancet Infect Dis 2017; 17:661–70.
- [5] Schmutzhard J, Glueckert R, Pritz C, et al. Sepsis otopathy: experimental sepsis leads to significant hearing impairment due to apoptosis and glutamate excitotoxicity in murine cochlea. Dis Model Mech 2013;6:745–54.
- [6] Fischer N, Mathonia NM, Hollerich G, et al. Surviving murine experimental sepsis affects the function and morphology of the inner ear. Biol Open 2017;6:732–40.
- [7] Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol 2000;5:3–22.
- [8] Oesterle EC. Changes in the adult vertebrate auditory sensory epithelium after trauma. Hear Res 2013;297:91–8.
- [9] Chou C-H, Lee J-T, Lin C-C, et al. Septicemia is associated with increased risk for dementia: a population-based longitudinal study. Oncotarget 2017;8:84300–8.

www.md-iournal.com

- [10] Ou S-M, Chu H, Chao P-W, et al. Long-term mortality and major adverse cardiovascular events in sepsis survivors: a nationwide population-based study. Am J Respir Crit Care Med 2016;194: 209–17.
- [11] Tsai C-L, Lee J-T, Lien L-M, et al. The association between septicemia and the risk of multiple sclerosis: a nationwide register-based retrospective cohort study in Taiwan. QJM 2018;111:605–11.
- [12] Worsøe L, Cayé-Thomasen P, Brandt CT, et al. Factors associated with the occurrence of hearing loss after pneumococcal meningitis. Clin Infect Dis 2010;51:917–24.
- [13] Ries PW. Prevalence and characteristics of persons with hearing trouble: United States 1990–91. Vital Health Stat 1990-91;1994: 1–75.
- [14] Hoffman HJ, Dobie RA, Losonczy KG, et al. Declining prevalence of hearing loss in US adults aged 20 to 69 years. JAMA Otolaryngol–Head Neck Surg 2017;143:274–85.
- [15] Kalinec GM, Lomberk G, Urrutia RA, et al. Resolution of cochlear inflammation: novel target for preventing or ameliorating drug-, noiseand age-related hearing loss. Front Cell Neurosci 2017;11:192.
- [16] Werdan K, Schmidt H, Ebelt H, et al. Impaired regulation of cardiac function in sepsis, SIRS, and MODS. This article is one of a selection of papers from the NATO Advanced Research Workshop on Translational Knowledge for Heart Health (published in part 2 of a 2-part Special Issue). Can J Physiol Pharmacol 2009;87:266–74.
- [17] Singer M. The role of mitochondrial dysfunction in sepsis-induced multiorgan failure. Virulence 2014;5:66–72.
- [18] Koo J-W, Quintanilla-Dieck L, Jiang M, et al. Endotoxemia-mediated inflammation potentiates aminoglycoside-induced ototoxicity. Sci Transl Med 2015;7:298ra118–1298ra.
- [19] Vilayur E, Gopinath B, Harris DC, et al. The association between reduced GFR and hearing loss: a cross-sectional population-based study. Am J Kidney Dis 2010;56:661–9.
- [20] Ishai R, Halpin CF, Shin JJ, et al. Long-term incidence and degree of sensorineural hearing loss in otosclerosis. Otol Neurotol 2016;37: 1489–96.
- [21] Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: prevention and management. J Res Med Sci 2015;20:1112–20.
- [22] Lin C-D, Wei I-H, Tsai M-H, et al. Changes in guinea pig cochlea after transient cochlear ischemia. Neuroreport 2010;21:968–75.
- [23] Olivetto E, Simoni E, Guaran V, et al. Sensorineural hearing loss and ischemic injury: development of animal models to assess vascular and oxidative effects. Hear Res 2015;327:58–68.
- [24] Segal S, Pollard A. Vaccines against bacterial meningitis. Br Med Bull 2004;72:65–81.
- [25] Hutchison BG, Oxman AD, Shannon HS, et al. Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician 1999; 45:2381–93.
- [26] Falcone M, Russo A, Cangemi R, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc 2015;4:e001595.
- [27] Chen Y, Azad M, Gibson S. Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ 2009;16:1040–52.
- [28] Levin A, Hemmelgarn B, Culleton B, et al. Guidelines for the management of chronic kidney disease. Can Med Assoc J 2008; 179:1154–62.
- [29] Washyna TJ, Netzer G, Langa KM, et al. Spurious inferences about longterm outcomes: the case of severe sepsis and geriatric conditions. Am J Respir Crit Care Med 2012;185:835–41.